Cargando…
Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer
PURPOSE: Breast cancer is the most common cancer among women. Pemetrexed, a new generation antifolate drug, is one of the primary treatments for breast cancer. However, multidrug resistance (MDR) in breast cancer greatly hampers the therapeutic efficacy of chemotherapies such as pemetrexed. Nanomedi...
Autores principales: | Bai, Fang, Yin, You, Chen, Ting, Chen, Jihui, Ge, Meixin, Lu, Yunshu, Xie, Fangyuan, Zhang, Jian, Wu, Kejin, Liu, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846754/ https://www.ncbi.nlm.nih.gov/pubmed/29563790 http://dx.doi.org/10.2147/IJN.S150237 |
Ejemplares similares
-
Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
por: Chen, Jihui, et al.
Publicado: (2021) -
Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
por: Chen, Jihui, et al.
Publicado: (2021) -
An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts
por: Chen, Qing, et al.
Publicado: (2017) -
Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar
por: Sun, Yue-Li, et al.
Publicado: (2013) -
Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)
por: DENG, WEN, et al.
Publicado: (2013)